Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sumithira Vasu

Showing results (71-80 of 102) with videos related to

Pageof 11
Sort By:
Journal of Clinical Medicine|July 2, 2021
Outcomes of Bone Marrow Compared to Peripheral Blood for Haploidentical TransplantationNidhi Sharma, Muhammad Salman Faisal, Qiuhong Zhao, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 5, 2019
BEAM versus BUCYVP16 Conditioning before Autologous Hematopoietic Stem Cell Transplant in Patients with Hodgkin LymphomaSara Singer, Robert Dean, Qiuhong Zhao, et al.
Molecular Cancer Therapeutics|February 7, 2020
Selective and Potent CDK8/19 Inhibitors Enhance NK-Cell Activity and Promote Tumor SurveillanceMarco H Hofmann, Rajeswaran Mani, Harald Engelhardt, et al.
Bone Marrow Transplantation|February 6, 2019
BEAM or BUCYVP16-conditioning regimen for autologous stem-cell transplantation in non-Hodgkin's lymphomasSara Singer, Nidhi Sharma, Robert Dean, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|September 2, 2020
Considerations for Use of Hematopoietic Growth Factors in Patients With Cancer Related to the COVID-19 PandemicElizabeth A Griffiths, Laura M Alwan, Kimo Bachiashvili, et al.
Journal for Immunotherapy of Cancer|August 25, 2021
Early toxicity and clinical outcomes after chimeric antigen receptor T-cell (CAR-T) therapy for lymphomaJonathan E Brammer, Zachary Braunstein, Aashish Katapadi, et al.
Journal of the American Heart Association|September 19, 2025
Presence of Clonal Hematopoiesis and Cardiac Events After Allogeneic Stem Cell TransplantationCooper Quartermaine, Zach Braunstein, Adnan Shaaban, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 18, 2025
Primary Results From Blood and Marrow Transplant Clinical Trials Network 1702: Clinical Transplant-Related Long-Term Outcomes of Alternative Donor Allogeneic TransplantationStephanie J Lee, Brent Logan, Mary M Horowitz, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 24, 2015
Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 InhibitorsMohamed Shanavas, Uday Popat, Laura C Michaelis, et al.
Blood|March 14, 2022
Impact of diagnostic genetics on remission MRD and transplantation outcomes in older patients with AMLH Moses Murdock, Haesook T Kim, Nathan Denlinger, et al.
Pageof 11

Showing results (71-80 of 102) with videos related to

Sort By:
Pageof 11
Journal of Clinical Medicine|July 2, 2021
Outcomes of Bone Marrow Compared to Peripheral Blood for Haploidentical TransplantationNidhi Sharma, Muhammad Salman Faisal, Qiuhong Zhao, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 5, 2019
BEAM versus BUCYVP16 Conditioning before Autologous Hematopoietic Stem Cell Transplant in Patients with Hodgkin LymphomaSara Singer, Robert Dean, Qiuhong Zhao, et al.
Molecular Cancer Therapeutics|February 7, 2020
Selective and Potent CDK8/19 Inhibitors Enhance NK-Cell Activity and Promote Tumor SurveillanceMarco H Hofmann, Rajeswaran Mani, Harald Engelhardt, et al.
Bone Marrow Transplantation|February 6, 2019
BEAM or BUCYVP16-conditioning regimen for autologous stem-cell transplantation in non-Hodgkin's lymphomasSara Singer, Nidhi Sharma, Robert Dean, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|September 2, 2020
Considerations for Use of Hematopoietic Growth Factors in Patients With Cancer Related to the COVID-19 PandemicElizabeth A Griffiths, Laura M Alwan, Kimo Bachiashvili, et al.
Journal for Immunotherapy of Cancer|August 25, 2021
Early toxicity and clinical outcomes after chimeric antigen receptor T-cell (CAR-T) therapy for lymphomaJonathan E Brammer, Zachary Braunstein, Aashish Katapadi, et al.
Journal of the American Heart Association|September 19, 2025
Presence of Clonal Hematopoiesis and Cardiac Events After Allogeneic Stem Cell TransplantationCooper Quartermaine, Zach Braunstein, Adnan Shaaban, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 18, 2025
Primary Results From Blood and Marrow Transplant Clinical Trials Network 1702: Clinical Transplant-Related Long-Term Outcomes of Alternative Donor Allogeneic TransplantationStephanie J Lee, Brent Logan, Mary M Horowitz, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 24, 2015
Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 InhibitorsMohamed Shanavas, Uday Popat, Laura C Michaelis, et al.
Blood|March 14, 2022
Impact of diagnostic genetics on remission MRD and transplantation outcomes in older patients with AMLH Moses Murdock, Haesook T Kim, Nathan Denlinger, et al.
Pageof 11